Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.
Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases
Objective: Estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the adult population using 2 US healthcare claims databases. Background: ET is a…Factors related to the antidepressant effect of safinamide in Parkinson’s disease. A post-hoc analysis of SADNESS-PD study
Objective: To assess the role of different factors in the antidepressant effect of safinamide in Parkinson’s disease (PD) Background: SADNESS-PD was a real-life, multicenter, retrospective…Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.
Objective: In this study we seek to compare characteristics and complications of patients suffering from advanced Parkinson's treated with duodenal levodopa infusion. Background: Motor fluctuations…Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease
Objective: Understand key efficacy outcomes used to assess adjunctive treatments to carbidopa/levodopa (CD/LD) for Parkinson’s disease (PD). Background: CD/LD is widely considered the most effective…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 36
- Next Page »